Navigation Links
AlphaRx Receives China Patent on Its Drug Delivery Platform
Date:8/10/2009

MARKHAM, ON, Aug. 10 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that it has been granted a comprehensive patent in China for its topical platform technology entitled "Vehicle For Topical Delivery of Anti-Inflammatory Compounds." The platform is an integral part of the Company's clinical stage product candidate Indaflex(TM).

"China represents a major opportunity for AlphaRx because of its huge and growing market for innovative therapeutics products," said AlphaRx President and CEO Michael Lee. "The granting of this patent from the Chinese government intellectual property authority helps protect our innovative drug delivery technology and further endorses our competitive position in China."

In April 2006, AlphaRx licensed the global rights (with the exception of Asia and Mexico) for Indaflex(TM) to Proprius Pharmaceuticals, Inc. Under the terms of the agreement, AlphaRx is eligible to receive milestone payments of up to $116 million for the successful development and commercialization of Indaflex(TM), as well as double-digit royalties on sales. Proprius was acquired by Cypress Biosceince Inc., in March 2008.

About Indaflex(TM)

Indaflex(TM) is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the symptomatic treatment of osteoarthritis. Arthritis is the most common chronic disease in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx's enhanced proprietary delivery system, the company believes its' clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex(TM) delivery, the company hopes, may circumvent the significant GI side-effects commonly found with orally ingested NSAID's.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

This press release is available on the company's official on-line investor relations site for investor commentary, feedback and questions.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Venturepharm Announce Collaboration Agreement
2. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
3. AlphaRx Unveils its China Strategy
4. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. AlphaRx Shareholder Update
7. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
8. AlphaRx Signs Cooperative Research and Development Agreement with US Army
9. AlphaRx Provides Corporate and Development Update
10. AlphaRxs Indaflex(TM) Continues its Clinical Development
11. AlphaRx CEO Accumulates More Company Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet ... RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s ... professionals, donating their time and skills to help hundreds of uninsured and underinsured people ...
(Date:2/12/2016)... Pass, OR (PRWEB) , ... February 12, 2016 ... ... contains an article about foods choices that promote eye health. These articles generally ... vision health. Water and health advocate Sharon Kleyne endorses every one of these ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce the ... in Norwalk, serves as the host site and directing the camps is PGA Professional ... had successful camps in recent years around Des Moines and are fortunate to have ...
(Date:2/12/2016)... SAN LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast ... purpose of this dance is to provide a night of fun for teens with and ... to help everyone feel welcomed and included at the event. The dance will take place ...
(Date:2/12/2016)... ... , ... Basketball is a game for everyone, not just those who can ... language translation is featured in the top right of the screen. Every technique that ... a sign language translator to teach kids the game and how to be as ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology: